期刊文献+

周永明治疗恶性肿瘤化疗后骨髓抑制的经验 被引量:9

Prof.Zhou Yongming's Experiences in Myelosuppression after Chemotherapy of Malignant Tumor
下载PDF
导出
摘要 骨髓抑制是恶性肿瘤(化学治疗)化疗后常见并发症之一,临床中常常影响治疗的进行,现代医学应用集落刺激因子(CSF)、血小板生成素(TPO)等取得一定疗效,但价格和其不稳定性临床受限,周永明教授具有深厚的中医功底及扎实的西医理论,应用中医理论联系现代免疫学研究,中西医结合,系统总结出健运脾胃,补益肝肾;调理脏腑,促进排泄;解毒祛邪,有利正复;辨病辨证,遣方选药;结合药理调节免疫等治法,在此指导下,应用中医药方药治疗化疗后骨髓抑制,常用方药有:香砂六君子汤、六味地黄丸、逍遥散、圣愈汤、泻白散,白花蛇舌草、半枝莲、连翘、车前子、鸡血藤、丹参等,效果显著,值得推广。 Myelosuppressionisoneofthecommoncomplicationsofchemotherapyformalignant tumor and it often affects the progression of treatment.Modern medicine achieves a certain efficacy on it with colony stimulating factor(CSF)and thrombopoietin(TPO).But its cost and instability limit the clinical prac-tice.Prof.Zhou Yongming has solid theoretic foundation of traditional Chinese medicine(TCM)and western medicine.He integrates TCMtheory with modern immunology study and summarizes systematically the experi-ences in the treatment based on strengthening the spleen and stomach,tonifying the liver and kidney;regula-ting zangfu function and promoting excretion,detoxification,removing pathogens and promoting the recovery;selecting the herbal formulas based on disease and symptom differentiation,and regulating the immunity.The common formulas and herbs for the treatment of myelosuppression after chemotherapy include Xiangsha Liu-junzi Tang;Liuwei Dihuang Wan,Xiaoyao San;Shengyu Tang;Xiebai San;hedyotis diffusa,sculellaria barba-ta,fuctus forsythiae,semen plantaginis,caulis spatholobi,and salvia miltiorrhiza.The efficacy is significant and this therapy deserves to be promoted.
出处 《世界中西医结合杂志》 2014年第7期697-699,共3页 World Journal of Integrated Traditional and Western Medicine
关键词 周永明 恶性肿瘤 骨髓抑制 经验 ZhouYongming MalignantTumor Myelosuppression Experiences
  • 相关文献

参考文献8

二级参考文献22

  • 1唐年亚,陈丽琛,邱幸凡,张六通.从六淫邪气论毒邪[J].湖北中医学院学报,2006,8(3):34-35. 被引量:12
  • 2SCHWARTZ R N. Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols[J]. Am J Health Syst Phann, 2007, 64(suppl 2) :5- 13.
  • 3GARFINKEL L, BORING C C, HEATH C W. Changing trends. An overview of breast cancer incidence and mortality[ J]. Jr Canc- er, 1994,74(1 Suppl):222-227.
  • 4VANSTEENKISTE J, PIRKER R, MASSUTI B, et al. Double- blind, placebo-controlled, randomized phase Ⅲ trial of darbepoet- in alfa in lung cancer patients receiving chemotherapy[ J]. J Natl Cancer lnst, 2002, 94(16) : 1211-1220.
  • 5LOMAN N, JOHANNSSON O, KRISTOFFERSSON U, et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a populatlon-based series of early-onset breast cancer[ J ] . J Natl Cancer Inst, 2001,93 (16) :1215-1223.
  • 6HESKETH P J, ARENA F, PATEL D, et al. A randomized con- trolled trial of darbepoetin alfa administered as a fixed or weight- based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies [ J ]. Cancer, 2004, 100 (4) : 859 -868.
  • 7CELLA D. Factors influencing quality of life in cancer patients : a- nemia and fatigue[J]. Semin Oncol, 1998, 25(suppl 7) :43-46.
  • 8KNOWLES G, BORTHWICK D, MCNAMARA S, et al. Survey of nurses' assessment of cancer-related fatigue [ J]. Eur J Cancer Care (Engl), 2000, 9(2) :105-113.
  • 9CURT G A, BREITBART W, CELLA D, et al. Impact of cancer- related fatigue on the lives of patients: new findings from the Fa- tigue Coalition [ J ]. Oncologist, 2000, 5 (5) :353-360.
  • 10朱震亨.丹溪心法[M].北京:人民卫生出版社,2005.233.

共引文献93

同被引文献216

引证文献9

二级引证文献166

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部